https://orcid.org/0000-0002-8160-4169
References
- Simon D, Braathen LR, Simon HU. Eosinophils and atopic dermatitis. Allergy. 2004;59(6):561–570.
- Valent P, Klion AD, Horny HP, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012;130(3):607–612.e9.
- Iurlo A, Cattaneo D, Gianelli U. Hypereosinophilic syndromes in the precision medicine era: clinical, molecular aspects and therapeutic approaches (targeted therapies). Expert Rev Hematol. 2019;12(12):1077–1088.
- Wollenberg A, Beck LA, Blauvelt A, et al. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). Br J Dermatol. 2020;182(5):1120–1135.
- Ariëns LFM, van der Schaft J, Spekhorst LS, et al. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the dutch BioDay registry. J Am Acad Dermatol. 2021;84(4):1000–1009.
- Beck LA, Thaçi D, Deleuran M, et al. Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study. J Dermatolog Treat. 2021;1–9. doi:10.1080/09546634.2020.1871463.
- Ahn J, Bae JY, Seo SJ. A retrospective case series hypereosinophilia during dupilumab treatment: hypereosinophilia could be a pharmacogenetic biomarker of dupilumab. Dermatol Ther. 2020;33(6):e13847.
- Jang DH, Heo SJ, Jung HJ, et al. Retrospective study of dupilumab treatment for moderate to severe atopic dermatitis in korea: efficacy and safety of dupilumab in Real-World practice. JCM. 2020;9(6):1982.
- Ferrucci S, Casazza G, Angileri L, et al. Clinical response and quality of life in patients with severe atopic dermatitis treated with dupilumab: a Single-Center Real-Life experience. JCM. 2020;9(3):791.
- Hamilton JD, Harel S, Swanson BN, et al. Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases. Clin Exp Allergy. 2021;51(7):915–931.
- Nettis E, Ferrucci SM, Ortoncelli M, et al. Use of dupilumab for 543 adult patients with Moderate-To-Severe atopic dermatitis: a multicenter, retrospective study. J Investig Allergol Clin Immunol. 2020;32(2):0.
- Kimura A, Takeda A, Ikebukuro T, et al. Serum IgE reduction and paradoxical eosinophilia associated with allergic conjunctivitis after dupilumab therapy. J Ophthalmic Inflamm Infect. 2021;11(1):3
- Akinlade B, Guttman-Yassky E, de Bruin-Weller M, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019;181(3):459–473.
- Katsuta M, Ishiuji Y, Matsuzaki H, et al. Transient increase in circulating basophils and eosinophils in dupilumab-associated conjunctivitis in patients with atopic Dermatitis. Acta Derm Venereol. 2021;101(6):adv00483
- Imai Y, Yasuda K, Nagai M, et al. IL-33-Induced atopic Dermatitis-Like inflammation in mice is mediated by group 2 innate lymphoid cells in concert with Basophils. J Invest Dermatol. 2019;139(10):2185–2194.e3.
- Utine CA, Li G, Asbell P, et al. Ocular surface disease associated with dupilumab treatment for atopic diseases. Ocul Surf. 2021;19:151–156.
- Kozera E, Stewart T, Gill K, et al. Dupilumab associated head and neck dermatitis is associated with elevated Pre-Treatment serum Malassezia-Specific immunoglobulin E: a multicenter, prospective cohort study. Br J Dermatol. 2022. doi:10.1111/bjd.21019.